Space could become the new frontier for longevity research. A British startup has just launched an autonomous lab the size of a grapefruit into orbit, aiming to study proteins responsible for age-related diseases such as Alzheimer's, Parkinson's, and certain cancers. The experiment, launched aboard a SpaceX rocket, is the first test of a system that could provide unique data impossible to obtain on Earth due to gravity.
An autonomous orbital lab to overcome Earth's gravity limitations
The device, developed by Mass Balance, contains chemicals, sensors, and control elements to maintain reactions in microgravity. Housed in a 10-centimeter pod built by Austrian company Tumbleweed, the experiment will orbit Earth for a few months, automatically measuring and beaming back data on how living cells grow, react, and function under weak gravity. According to Toby Call, co-founder and CEO of Mass Balance, "when you take away gravity, a lot of weird and wonderful things happen, some of which will be very valuable for life sciences and pharma." The stated goal is to make space "boring, reliable, and just another research environment."
Sponsored Protocol
Disordered proteins: the target of space longevity missions
The microgravity environment could be crucial for studying disordered proteins, a group of molecules that constantly change shape on Earth, making them difficult to analyze with traditional techniques. This instability creates a gap in training data for AI models like Google's AlphaFold, which cannot predict how these proteins will behave and respond to drugs. Space, however, may offer ideal conditions for studying them. Mass Balance plans to generate data by running tests on disordered proteins under microgravity and use it to train an AI model adapter that fills in the gaps. The model, data licensing, and data access will drive revenue for the company.
Sponsored Protocol
Initial test: an industrial biocatalyst to verify the system
For now, the mission focuses on testing the operating system and data capture. The payload includes an industrial biocatalyst that will break down another chemical compound. The platform will monitor the process using light to confirm that the chemical reaction occurs as planned. This first step is critical to prove that automation works in orbit, before moving to more complex protein experiments. Unlike other startups such as BioOrbit and Varda Space Industries, which aim to bring samples back to Earth, Mass Balance does not plan to recover the system, avoiding the engineering challenges of atmospheric reentry.
Sponsored Protocol
A new tool for pharmaceutical research
Microgravity represents a new and underutilized tool for biomedical research. While other companies are developing orbital labs for drug crystallization, Mass Balance focuses on generating high-quality data to improve AI models for drug discovery. The British startup joins a growing ecosystem, including initiatives like AI deepfakes in sports, showcasing the versatility of artificial intelligence. With this mission, Mass Balance hopes to pave the way for a new era of space-based health research. Source.
Source: https://www.wired.com/story/british-space-startup-launches-longevity-lab-into-orbit
